SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...
WASHINGTON (Reuters) - GlaxoSmithKline's Votrient extended the lives of a significant number of patients suffering from an aggressive form of cancer without the disease getting worse, but the drug did ...
Immune checkpoint blockade therapy works by preventing the binding of checkpoint and partner proteins, thereby allowing T cells to continue their work of attacking and killing cancer cells. A team ...
Small blue round cells of Ewing Sarcoma. Nat Pernick, CC BY 3.0, via Wikimedia Commons Ewing sarcoma is one of the most common bone cancers seen in children, and if it spreads, it can be deadly. A ...
Fragmented care - receiving medical treatment at more than one facility - has been associated with both positive and negative outcomes for cancer patients depending on a number of factors such as ...
The International Soft-Tissue Sarcoma Consortium (INSTRuCT) has issued a new consensus document outlining optimal treatment ...
Novel combination with neoadjuvant eftilagimod alfa (efti) achieves significant 51.5% tumour hyalinization/fibrosis across multiple soft tissue ...
Outpatient Biochemotherapy With Interleukin-2 and Interferon Alfa-2b in Patients With Metastatic Malignant Melanoma: Results of Two Phase II Cytokine Working Group Trials PURPOSE: To determine whether ...
Eftilagimod alfa and Keytruda with radiotherapy improved tumor hyalinization/fibrosis rates in resectable soft tissue sarcoma, surpassing the trial's primary endpoint. The combination therapy achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback